Navigation Links
Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Date:7/15/2008

- Company Reports Favorable Phase 1 RX-3341 Results -

NEW HAVEN, Conn., July 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the initiation of a Phase 2 clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections (cSSSIs). The safety and efficacy study will be conducted at 35 sites across the United States. As a precursor to this news the Company also announced positive results of a two-part Phase 1 study with the same candidate.

"We have made significant progress in advancing this next-generation broad spectrum antibiotic further toward clinical use," said Dr. Susan Froshauer, President and CEO of Rib-X. "We intend to rapidly move forward with the development of our IV dosage form to meet the need for a broad-spectrum antibiotic in the hospital setting, particularly one that is active against quinolone-resistant MRSA. We also hope to further progress our oral dosage form to ensure a greater diversity of use in the treatment of serious infections in a number of settings."

Phase 2 Study Design

This Phase 2 double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized cSSSI patients every 12 hours for 5 to 14 days, as compared to tigecycline (Tygacil(TM)). The study's primary endpoint is the assessment of RX-3341 efficacy, safety and tolerability at the two different doses compared to that of tigecycline's standard dosing regimen. A secondary endpoint for the study is the assessment of clinical efficacy of RX-3341 compared to tigecycline in patients with cSSSIs caused by methicillin- resistant Staphylococcus aureus (MRSA).

Phase I Results

The two-part Phase 1 stud
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
4. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
5. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. Isis Pharmaceuticals Conference Call Notice
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4
... BOSTON, Oct. 6, 2011 Solos Endoscopy, Inc. (OTCPK: ... support the National Breast Cancer Foundation (NBCF) by donating ... Instrument line for the month of October to the ... to hospitals across the Country through direct sales channels ...
... of dying from a heart attack is more than a fear ... reality. The mortality and morbidity rates for heart disease ... highest in Ohio, according to federal and state data. ... Regional Commission that will soon change. The federal grant will be ...
Cached Medicine Technology:Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals 2Grant Will Help Save Lives in Appalachian Ohio 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving forward ... meeting took place to discuss the next steps in ... court’s mass tort program. Attorneys for the plaintiffs and ... the Complex Litigation Center in Philadelphia’s City Hall where ... Risperdal lawsuits filed against Johnson & Johnson and its ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... KS (PRWEB) September 19, 2014 Unbound ... responding to families in regions of the Philippines being affected ... , More than 1,060 families evacuated to the nearest public ... Fung-Wong brought heavy rain and gusty winds to portions of ... causing heavy flooding. Some homes filled with more than 10 ...
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... ... Point Solutions has been awarded the prestigious Gold certification from Cisco ... specialization. The Certification recognizes High Point,s expert level of achievement ... Communication, and Data Center. Gold Certified Partners are considered extensions of ...
... Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous ... portfolio. , GENova owns the rights to a range ... all of them. The patents have not yet been ... been brought to GENova,s attention that previous releases were ...
... ... chiropractor, has taken over Optimal Body Chiropractic within Tuscan Sun Massage & Wellness in ... all ages by enhancing the relationship between the spine, nervous system, and the rest ... ...
... Public Health has been awarded $18.4 million by the ... Department of Defense to establish an Extremity Trauma Clinical ... coordinating center for the Consortium that includes a network ... several major military treatment centers and the U.S. Army ...
... young adults with acoustic neuromas , FRIDAY, Sept. 11 (HealthDay ... her mother,s voice or the sound of a dog barking. ... she had neurofibromatosis type 2 (NF2), a condition characterized by ... damaged the eighth cranial nerve in one ear. , The ...
... Sept. 11 United American Healthcare Corporation (Nasdaq: UAHC ... fourth fiscal quarter and full year ended June 30, 2009 on ... to file its Form 10-K for the period ended June 30, ... in compliance with applicable regulations. In addition, the Company announced ...
Cached Medicine News:Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:GENova issues clarifying press release 2Health News:Chiropractic Helps Strengthen Immune System and Prevent Sickness 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:United American Healthcare Corporation Announces Release Date for Fiscal 2009 Fourth Quarter and Full Year Results 2